Supplementary Figures 1-6 from Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity Article Swipe

View

Eva Sum , Moritz Rapp , Philipp Fröbel , Marine Le Clech , Harald Dürr , Anna Maria Giusti , Mario Perro , Dario Speziale , Leo Kunz , Elena Menietti , Peter Brünker , Ulrike Hopfer , Martin Lechmann , Andrzej Sobieniecki , Birte Appelt , Roberto Adelfio , Valeria Nicolini , Anne Freimoser–Grundschober , Whitney Jordaan , Sara Labiano , Felix Weber , Thomas Emrich , François Christen , Birgit Essig , Pedro Romero , Christine Trumpfheller , Pablo Umaña ·

YOU? · · 2023 · Open Access · · DOI: https://doi.org/10.1158/1078-0432.22480199

Supplementary Figure 1 shows more details on the mode of action and design of the used antibodies. Supplementary Figure 2 displays additional APC activation data of the human and murine FAP-CD40 molecules. Supplementary Figure 3 shows additional data for FRC in vitro assays and the OVA vaccination study. Supplementary Figure 4 shows additional data on the in vivo study comparing FAP-huCD40 and SGN40 moIgG1. Supplementary Figure 5 displays additional data on the in vivo comparison of selicrelumab and FAP-huCD40. Supplementary Figure 6 shows the data of a FAP-huCD40 dose escalation study in cynomolgus monkeys.

Related Topics

Concepts

In vivo Pharmacology CD40 Medicine In vitro Chemistry Biology Biochemistry Biotechnology Cytotoxic T cell

Metadata

Type: preprint
Language: en
Landing Page: https://doi.org/10.1158/1078-0432.22480199
OA Status: gold
Related Works: 10
OpenAlex ID: https://openalex.org/W4361815648

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4361815648

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1158/1078-0432.22480199

Digital Object Identifier
Title: Supplementary Figures 1-6 from Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity

Work title
Type: preprint

OpenAlex work type
Language: en

Primary language
Publication year: 2023

Year of publication
Publication date: 2023-03-31

Full publication date if available
Authors: Eva Sum, Moritz Rapp, Philipp Fröbel, Marine Le Clech, Harald Dürr, Anna Maria Giusti, Mario Perro, Dario Speziale, Leo Kunz, Elena Menietti, Peter Brünker, Ulrike Hopfer, Martin Lechmann, Andrzej Sobieniecki, Birte Appelt, Roberto Adelfio, Valeria Nicolini, Anne Freimoser–Grundschober, Whitney Jordaan, Sara Labiano, Felix Weber, Thomas Emrich, François Christen, Birgit Essig, Pedro Romero, Christine Trumpfheller, Pablo Umaña

List of authors in order
Landing page: https://doi.org/10.1158/1078-0432.22480199

Publisher landing page
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://doi.org/10.1158/1078-0432.22480199

Direct OA link when available
Concepts: In vivo, Pharmacology, CD40, Medicine, In vitro, Chemistry, Biology, Biochemistry, Biotechnology, Cytotoxic T cell

Top concepts (fields/topics) attached by OpenAlex
Cited by: 0

Total citation count in OpenAlex
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4361815648
doi	https://doi.org/10.1158/1078-0432.22480199
ids.doi	https://doi.org/10.1158/1078-0432.22480199
ids.openalex	https://openalex.org/W4361815648
fwci	0.0
type	preprint
title	Supplementary Figures 1-6 from Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
topics[0].id	https://openalex.org/T12505
topics[0].field.id	https://openalex.org/fields/27
topics[0].field.display_name	Medicine
topics[0].score	0.9993000030517578
topics[0].domain.id	https://openalex.org/domains/4
topics[0].domain.display_name	Health Sciences
topics[0].subfield.id	https://openalex.org/subfields/2730
topics[0].subfield.display_name	Oncology
topics[0].display_name	Peptidase Inhibition and Analysis
topics[1].id	https://openalex.org/T10158
topics[1].field.id	https://openalex.org/fields/27
topics[1].field.display_name	Medicine
topics[1].score	0.9829999804496765
topics[1].domain.id	https://openalex.org/domains/4
topics[1].domain.display_name	Health Sciences
topics[1].subfield.id	https://openalex.org/subfields/2730
topics[1].subfield.display_name	Oncology
topics[1].display_name	Cancer Immunotherapy and Biomarkers
topics[2].id	https://openalex.org/T12996
topics[2].field.id	https://openalex.org/fields/13
topics[2].field.display_name	Biochemistry, Genetics and Molecular Biology
topics[2].score	0.9815999865531921
topics[2].domain.id	https://openalex.org/domains/1
topics[2].domain.display_name	Life Sciences
topics[2].subfield.id	https://openalex.org/subfields/1305
topics[2].subfield.display_name	Biotechnology
topics[2].display_name	Cancer Research and Treatments
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C207001950
concepts[0].level	2
concepts[0].score	0.6646555066108704
concepts[0].wikidata	https://www.wikidata.org/wiki/Q141124
concepts[0].display_name	In vivo
concepts[1].id	https://openalex.org/C98274493
concepts[1].level	1
concepts[1].score	0.5092226266860962
concepts[1].wikidata	https://www.wikidata.org/wiki/Q128406
concepts[1].display_name	Pharmacology
concepts[2].id	https://openalex.org/C39347974
concepts[2].level	4
concepts[2].score	0.48404043912887573
concepts[2].wikidata	https://www.wikidata.org/wiki/Q21135811
concepts[2].display_name	CD40
concepts[3].id	https://openalex.org/C71924100
concepts[3].level	0
concepts[3].score	0.4718453884124756
concepts[3].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[3].display_name	Medicine
concepts[4].id	https://openalex.org/C202751555
concepts[4].level	2
concepts[4].score	0.4386656582355499
concepts[4].wikidata	https://www.wikidata.org/wiki/Q221681
concepts[4].display_name	In vitro
concepts[5].id	https://openalex.org/C185592680
concepts[5].level	0
concepts[5].score	0.2577453851699829
concepts[5].wikidata	https://www.wikidata.org/wiki/Q2329
concepts[5].display_name	Chemistry
concepts[6].id	https://openalex.org/C86803240
concepts[6].level	0
concepts[6].score	0.2313489019870758
concepts[6].wikidata	https://www.wikidata.org/wiki/Q420
concepts[6].display_name	Biology
concepts[7].id	https://openalex.org/C55493867
concepts[7].level	1
concepts[7].score	0.07192191481590271
concepts[7].wikidata	https://www.wikidata.org/wiki/Q7094
concepts[7].display_name	Biochemistry
concepts[8].id	https://openalex.org/C150903083
concepts[8].level	1
concepts[8].score	0.0
concepts[8].wikidata	https://www.wikidata.org/wiki/Q7108
concepts[8].display_name	Biotechnology
concepts[9].id	https://openalex.org/C154317977
concepts[9].level	3
concepts[9].score	0.0
concepts[9].wikidata	https://www.wikidata.org/wiki/Q376266
concepts[9].display_name	Cytotoxic T cell
keywords[0].id	https://openalex.org/keywords/in-vivo
keywords[0].score	0.6646555066108704
keywords[0].display_name	In vivo
keywords[1].id	https://openalex.org/keywords/pharmacology
keywords[1].score	0.5092226266860962
keywords[1].display_name	Pharmacology
keywords[2].id	https://openalex.org/keywords/cd40
keywords[2].score	0.48404043912887573
keywords[2].display_name	CD40
keywords[3].id	https://openalex.org/keywords/medicine
keywords[3].score	0.4718453884124756
keywords[3].display_name	Medicine
keywords[4].id	https://openalex.org/keywords/in-vitro
keywords[4].score	0.4386656582355499
keywords[4].display_name	In vitro
keywords[5].id	https://openalex.org/keywords/chemistry
keywords[5].score	0.2577453851699829
keywords[5].display_name	Chemistry
keywords[6].id	https://openalex.org/keywords/biology
keywords[6].score	0.2313489019870758
keywords[6].display_name	Biology
keywords[7].id	https://openalex.org/keywords/biochemistry
keywords[7].score	0.07192191481590271
keywords[7].display_name	Biochemistry
language	en
locations[0].id	doi:10.1158/1078-0432.22480199
locations[0].is_oa	True
locations[0].source
locations[0].license	cc-by
locations[0].pdf_url
locations[0].version	acceptedVersion
locations[0].raw_type	posted-content
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	False
locations[0].raw_source_name
locations[0].landing_page_url	https://doi.org/10.1158/1078-0432.22480199
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5041981120
authorships[0].author.orcid	https://orcid.org/0000-0002-0082-9500
authorships[0].author.display_name	Eva Sum
authorships[0].author_position	first
authorships[0].raw_author_name	Eva Sum
authorships[0].is_corresponding	False
authorships[1].author.id	https://openalex.org/A5015837678
authorships[1].author.orcid	https://orcid.org/0000-0001-5104-7683
authorships[1].author.display_name	Moritz Rapp
authorships[1].author_position	middle
authorships[1].raw_author_name	Moritz Rapp
authorships[1].is_corresponding	False
authorships[2].author.id	https://openalex.org/A5065468159
authorships[2].author.orcid
authorships[2].author.display_name	Philipp Fröbel
authorships[2].author_position	middle
authorships[2].raw_author_name	Philipp Fröbel
authorships[2].is_corresponding	False
authorships[3].author.id	https://openalex.org/A5026289091
authorships[3].author.orcid
authorships[3].author.display_name	Marine Le Clech
authorships[3].author_position	middle
authorships[3].raw_author_name	Marine Le Clech
authorships[3].is_corresponding	False
authorships[4].author.id	https://openalex.org/A5002226100
authorships[4].author.orcid
authorships[4].author.display_name	Harald Dürr
authorships[4].author_position	middle
authorships[4].raw_author_name	Harald Dürr
authorships[4].is_corresponding	False
authorships[5].author.id	https://openalex.org/A5024188748
authorships[5].author.orcid	https://orcid.org/0000-0002-5694-3732
authorships[5].author.display_name	Anna Maria Giusti
authorships[5].author_position	middle
authorships[5].raw_author_name	Anna Maria Giusti
authorships[5].is_corresponding	False
authorships[6].author.id	https://openalex.org/A5026544482
authorships[6].author.orcid	https://orcid.org/0000-0003-1375-8155
authorships[6].author.display_name	Mario Perro
authorships[6].author_position	middle
authorships[6].raw_author_name	Mario Perro
authorships[6].is_corresponding	False
authorships[7].author.id	https://openalex.org/A5038802855
authorships[7].author.orcid
authorships[7].author.display_name	Dario Speziale
authorships[7].author_position	middle
authorships[7].raw_author_name	Dario Speziale
authorships[7].is_corresponding	False
authorships[8].author.id	https://openalex.org/A5066305023
authorships[8].author.orcid	https://orcid.org/0000-0001-7332-3343
authorships[8].author.display_name	Leo Kunz
authorships[8].author_position	middle
authorships[8].raw_author_name	Leo Kunz
authorships[8].is_corresponding	False
authorships[9].author.id	https://openalex.org/A5002042787
authorships[9].author.orcid	https://orcid.org/0000-0002-5699-8725
authorships[9].author.display_name	Elena Menietti
authorships[9].author_position	middle
authorships[9].raw_author_name	Elena Menietti
authorships[9].is_corresponding	False
authorships[10].author.id	https://openalex.org/A5080071412
authorships[10].author.orcid
authorships[10].author.display_name	Peter Brünker
authorships[10].author_position	middle
authorships[10].raw_author_name	Peter Brünker
authorships[10].is_corresponding	False
authorships[11].author.id	https://openalex.org/A5026955443
authorships[11].author.orcid
authorships[11].author.display_name	Ulrike Hopfer
authorships[11].author_position	middle
authorships[11].raw_author_name	Ulrike Hopfer
authorships[11].is_corresponding	False
authorships[12].author.id	https://openalex.org/A5005225268
authorships[12].author.orcid
authorships[12].author.display_name	Martin Lechmann
authorships[12].author_position	middle
authorships[12].raw_author_name	Martin Lechmann
authorships[12].is_corresponding	False
authorships[13].author.id	https://openalex.org/A5060412049
authorships[13].author.orcid
authorships[13].author.display_name	Andrzej Sobieniecki
authorships[13].author_position	middle
authorships[13].raw_author_name	Andrzej Sobieniecki
authorships[13].is_corresponding	False
authorships[14].author.id	https://openalex.org/A5056208445
authorships[14].author.orcid
authorships[14].author.display_name	Birte Appelt
authorships[14].author_position	middle
authorships[14].raw_author_name	Birte Appelt
authorships[14].is_corresponding	False
authorships[15].author.id	https://openalex.org/A5021326463
authorships[15].author.orcid
authorships[15].author.display_name	Roberto Adelfio
authorships[15].author_position	middle
authorships[15].raw_author_name	Roberto Adelfio
authorships[15].is_corresponding	False
authorships[16].author.id	https://openalex.org/A5077770252
authorships[16].author.orcid	https://orcid.org/0000-0003-4306-7849
authorships[16].author.display_name	Valeria Nicolini
authorships[16].author_position	middle
authorships[16].raw_author_name	Valeria Nicolini
authorships[16].is_corresponding	False
authorships[17].author.id	https://openalex.org/A5056556748
authorships[17].author.orcid	https://orcid.org/0000-0001-5715-3639
authorships[17].author.display_name	Anne Freimoser–Grundschober
authorships[17].author_position	middle
authorships[17].raw_author_name	Anne Freimoser-Grundschober
authorships[17].is_corresponding	False
authorships[18].author.id	https://openalex.org/A5016320178
authorships[18].author.orcid	https://orcid.org/0000-0002-4973-9274
authorships[18].author.display_name	Whitney Jordaan
authorships[18].author_position	middle
authorships[18].raw_author_name	Whitney Jordaan
authorships[18].is_corresponding	False
authorships[19].author.id	https://openalex.org/A5077791294
authorships[19].author.orcid	https://orcid.org/0000-0002-2173-9416
authorships[19].author.display_name	Sara Labiano
authorships[19].author_position	middle
authorships[19].raw_author_name	Sara Labiano
authorships[19].is_corresponding	False
authorships[20].author.id	https://openalex.org/A5076327726
authorships[20].author.orcid	https://orcid.org/0000-0003-3367-5795
authorships[20].author.display_name	Felix Weber
authorships[20].author_position	middle
authorships[20].raw_author_name	Felix Weber
authorships[20].is_corresponding	False
authorships[21].author.id	https://openalex.org/A5016075040
authorships[21].author.orcid	https://orcid.org/0000-0003-1179-4697
authorships[21].author.display_name	Thomas Emrich
authorships[21].author_position	middle
authorships[21].raw_author_name	Thomas Emrich
authorships[21].is_corresponding	False
authorships[22].author.id	https://openalex.org/A5032847382
authorships[22].author.orcid
authorships[22].author.display_name	François Christen
authorships[22].author_position	middle
authorships[22].raw_author_name	François Christen
authorships[22].is_corresponding	False
authorships[23].author.id	https://openalex.org/A5081708347
authorships[23].author.orcid
authorships[23].author.display_name	Birgit Essig
authorships[23].author_position	middle
authorships[23].raw_author_name	Birgit Essig
authorships[23].is_corresponding	False
authorships[24].author.id	https://openalex.org/A5101424852
authorships[24].author.orcid	https://orcid.org/0000-0002-9688-2882
authorships[24].author.display_name	Pedro Romero
authorships[24].author_position	middle
authorships[24].raw_author_name	Pedro Romero
authorships[24].is_corresponding	False
authorships[25].author.id	https://openalex.org/A5083188070
authorships[25].author.orcid
authorships[25].author.display_name	Christine Trumpfheller
authorships[25].author_position	middle
authorships[25].raw_author_name	Christine Trumpfheller
authorships[25].is_corresponding	False
authorships[26].author.id	https://openalex.org/A5040318787
authorships[26].author.orcid	https://orcid.org/0000-0001-8206-2771
authorships[26].author.display_name	Pablo Umaña
authorships[26].author_position	last
authorships[26].raw_author_name	Pablo Umaña
authorships[26].is_corresponding	False
has_content.pdf	False
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://doi.org/10.1158/1078-0432.22480199
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	Supplementary Figures 1-6 from Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity
has_fulltext	False
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T12505
primary_topic.field.id	https://openalex.org/fields/27
primary_topic.field.display_name	Medicine
primary_topic.score	0.9993000030517578
primary_topic.domain.id	https://openalex.org/domains/4
primary_topic.domain.display_name	Health Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2730
primary_topic.subfield.display_name	Oncology
primary_topic.display_name	Peptidase Inhibition and Analysis
related_works	https://openalex.org/W2138350991, https://openalex.org/W1566729005, https://openalex.org/W2409285845, https://openalex.org/W2434195791, https://openalex.org/W1994342570, https://openalex.org/W3015376786, https://openalex.org/W1700716001, https://openalex.org/W2054843986, https://openalex.org/W2116210813, https://openalex.org/W2440701365
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.1158/1078-0432.22480199
best_oa_location.is_oa	True
best_oa_location.source
best_oa_location.license	cc-by
best_oa_location.pdf_url
best_oa_location.version	acceptedVersion
best_oa_location.raw_type	posted-content
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	https://doi.org/10.1158/1078-0432.22480199
primary_location.id	doi:10.1158/1078-0432.22480199
primary_location.is_oa	True
primary_location.source
primary_location.license	cc-by
primary_location.pdf_url
primary_location.version	acceptedVersion
primary_location.raw_type	posted-content
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	https://doi.org/10.1158/1078-0432.22480199
publication_date	2023-03-31
publication_year	2023
referenced_works_count	0
abstract_inverted_index.1	2
abstract_inverted_index.2	19
abstract_inverted_index.3	34
abstract_inverted_index.4	50
abstract_inverted_index.5	66
abstract_inverted_index.6	81
abstract_inverted_index.a	86
abstract_inverted_index.in	40, 56, 72, 91
abstract_inverted_index.of	9, 13, 25, 75, 85
abstract_inverted_index.on	6, 54, 70
abstract_inverted_index.APC	22
abstract_inverted_index.FRC	39
abstract_inverted_index.OVA	45
abstract_inverted_index.and	11, 28, 43, 61, 77
abstract_inverted_index.for	38
abstract_inverted_index.the	7, 14, 26, 44, 55, 71, 83
abstract_inverted_index.data	24, 37, 53, 69, 84
abstract_inverted_index.dose	88
abstract_inverted_index.mode	8
abstract_inverted_index.more	4
abstract_inverted_index.used	15
abstract_inverted_index.vivo	57, 73
abstract_inverted_index.SGN40	62
abstract_inverted_index.human	27
abstract_inverted_index.shows	3, 35, 51, 82
abstract_inverted_index.study	58, 90
abstract_inverted_index.vitro	41
abstract_inverted_index.Figure	1, 18, 33, 49, 65, 80
abstract_inverted_index.action	10
abstract_inverted_index.assays	42
abstract_inverted_index.design	12
abstract_inverted_index.murine	29
abstract_inverted_index.study.	47
abstract_inverted_index.details	5
abstract_inverted_index.moIgG1.	63
abstract_inverted_index.FAP-CD40	30
abstract_inverted_index.displays	20, 67
abstract_inverted_index.comparing	59
abstract_inverted_index.FAP-huCD40	60, 87
abstract_inverted_index.activation	23
abstract_inverted_index.additional	21, 36, 52, 68
abstract_inverted_index.comparison	74
abstract_inverted_index.cynomolgus	92
abstract_inverted_index.escalation	89
abstract_inverted_index.molecules.	31
abstract_inverted_index.FAP-huCD40.	78
abstract_inverted_index.antibodies.	16
abstract_inverted_index.vaccination	46
abstract_inverted_index.selicrelumab	76
abstract_inverted_index.Supplementary	17, 32, 48, 64, 79
abstract_inverted_index.monkeys.</p>	93
abstract_inverted_index.<p>Supplementary	0
cited_by_percentile_year
countries_distinct_count	0
institutions_distinct_count	27
sustainable_development_goals[0].id	https://metadata.un.org/sdg/3
sustainable_development_goals[0].score	0.75
sustainable_development_goals[0].display_name	Good health and well-being
citation_normalized_percentile.value	0.07204296
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False